Physician profile
Leonard Thomas Hackett
NPI 1669466868
$8,839.74
in general payments reported to CMS, 2019-2025
49 companies · $732 in 2025
The $732 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,220 · 2020: $494 · 2021: $1,640 · 2022: $1,801 · 2023: $1,524 · 2024: $1,428 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,476 · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,475.77 |
| Education | $208.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,213.32 | 2019-2024 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $802.30 | 2021-2025 | Lynparza, Enhertu, Imfinzi |
| Celgene Corporation | $764.39 | 2021-2025 | Opdualag, Pomalyst, Reblozyl |
| Glaxosmithkline, LLC. | $567.10 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Amgen INC. | $399.92 | 2020-2022 | |
| Astellas Pharma US INC | $399.82 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $390.87 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $360.32 | 2020-2025 | Tazverik, Onivyde |
| Exelixis INC. | $328.30 | 2019-2025 | Cabometyx |
| Incyte Corporation | $307.91 | 2021-2023 | Jakafi, Monjuvi |
| Abbvie INC. | $302.71 | 2019-2025 | |
| Genentech USA, INC. | $248.94 | 2019-2023 | Polivy |
| Pharmacyclics LLC, An Abbvie Company | $218.88 | 2021-2023 | Epkinly, Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $190.81 | 2019-2023 | Iclusig |
| Sirtex Medical INC | $169.43 | 2019-2024 | Sir-Spheres Microspheres |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Hackett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.